|Dr. Cameron Geoffrey McDonough M.D.||President, CEO & Director||939.09k||N/A||1970|
|Dr. Matthew Norkunas M.B.A., M.D.||Chief Financial Officer||611.11k||N/A||1978|
|Dr. Matthew Stanton Ph.D.||Chief Scientific Officer||654.83k||N/A||1973|
|Dr. Douglas Kerr M.B.A., M.D., Ph.D.||Chief Medical Officer||659.1k||N/A||1967|
|Dr. Tracy Zimmermann Ph.D.||Chief Development Officer||622.74k||N/A||1970|
|Dr. Mark D. Angelino Ph.D.||Co-Founder||N/A||N/A||1973|
|Dr. Robert Kotin Ph.D.||Co-Founder||N/A||N/A||1956|
|Ms. Antoinette Paone M.B.A., M.S.||Chief Operating Officer||N/A||N/A||1978|
|Ms. Yalonda Howze J.D.||Chief Legal Officer & Secretary||N/A||N/A||1972|
|Ms. Jasmin Tower||Senior Vice President of People & Operations||N/A||N/A||N/A|
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.’s ISS Governance QualityScore as of December 1, 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.